AIM ImmunoTech completes dosing in pancreatic cancer trial
AIM ImmunoTech (AIM) completed dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with results expected in 2027. The trial tests Ampligen with AstraZeneca's Imfinzi. AIM reported Q3 2026 cash of $6.9M, R&D expenses of $846K, and a net loss of $3.1M. The company secured patents for Ampligen combinations and repaid a promissory note.
How this was made
The 30-second read
Why it matters
The dosing milestone moves the company closer to a data readout that could materially affect valuation, but short‑term price movement is likely muted until efficacy results are released.
Market read
Primary biotech news with limited immediate market impact; relevance peaks around the upcoming efficacy readout.
What to watch
The company's cash runway is limited (~$7 M), which could constrain further development if additional funding is not secured.
Background
AIM ImmunoTech is a micro‑cap biotech focused on TLR‑3 agonist Ampligen, pursuing multiple oncology and infectious disease programs.
Ticker impact
AIM ImmunoTech announced completion of dosing in its Phase 2 DURIPANC trial for metastatic pancreatic cancer.
potential slight upward pressure as investors price in upcoming efficacy data.
No efficacy data yet, but trial advancement is a positive catalyst for a micro‑cap biotech.
Market effects
Adds to the pipeline momentum for pancreatic cancer immunotherapies, modestly supporting the biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance beyond niche oncology investors.
Counterpoint
Without efficacy data, the trial completion may be over‑hyped; the stock could remain flat or decline if results disappoint.
Key entities
- partnerAstraZeneca
Provides Imfinzi, the checkpoint inhibitor combined with Ampligen in the trial.
- partnerRevolution Medicines
Potential collaborator on RAS‑targeted combination therapies.
